Adagene Inc.
corporate_fare Company Profile
Adagene Inc. (NASDAQ:ADAG) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for ADAG at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-22, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for ADAG spans 6-K, SCHEDULE 13D/A, 424B5, 20-F.
Recent high-impact activity:
- Adagene Secures NMPA Clearance to Launch Phase 1 Trial for ADG138, a Double-Masked HER2xCD3 T-Cell Engager
- NMPA Clears Adagene's IND for ADG138, a Double-Masked HER2xCD3 T-Cell Engager
- Adagene Reports H1 2026 Results: $127.9M Cash, Runway into Late 2028, Muzastotug Phase 2 Data Expected 1H 2027
- Adagene's Muzastotug Shows 31% ORR in MSS CRC, Cash Runway Extended to Late 2028
- Adagene Reports Strong Unaudited Cash Position of $127.9 Million
Financial Snapshot
Short Interest & Short Volume
10.17 days to coverFINRA reported short interest of 2,101,495 shares in ADAG as of the September 15, 2026 settlement, a 1.4% increase from the prior period — about 10.2 days to cover at its recent average daily volume. On October 2, 2026, 34.4% of ADAG volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
ADAG files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.